Mohammed Al-Adhami

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

Christian Manegold, Donald Gravenor, Donald Woytowitz et al. · Journal of Clinical Oncology · 2008 · 167 citations · Full text

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus

John G. McHutchison, Bruce R. Bacon, Stuart C. Gordon et al. · Hepatology · 2007 · 112 citations · Full text

Immunodeficiencies, Viral Immunity, Immunology +17

Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response

Claire‐Anne Siegrist, Maria Pihlgren, Chantal Tougne et al. · Vaccine · 2004 · 107 citations

Vaccination, Vaccine Development, Viral Hepatitis +5

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial

Régis Peffault de Latour, Jeff Szer, Ilene C. Weitz et al. · The Lancet Haematology · 2022 · 65 citations

Chronic Kidney Disease, Hematology, Pegcetacoplan Versus Eculizumab +4

Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria

Raymond Wong, Juan Ramon Navarro-Cabrera, Narcisa Sonia Comia et al. · Blood Advances · 2023 · 51 citations · Full text